Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Summary

The aim of this study is to explore the effect of newly added SGLT2I medication or placebo, to standard medication regimen in diabetic patients with documented stable coronary disease. Therefore, in the present study the investigators plan to focus on possible anti-inflammatory and athero-thrombotic protective effects of Dapagliflozin compared to placebo, in secondary prevention population of stable coronary patients with diabetes. Additionally, the investigators will explore NT proBNP dynamics, which related to ventricular filling pressures in this specific population.

Timeline

Start

2018-02-01

Primary completion

2018-08-31

Completion

2018-12-31

Drugs

Indications